Sydney Lupkin
Stories
-
He invented a successful medical device as a student. Here's his advice for new grads
When Thorsten Siess was in graduate school, he came up with the idea for a heart device that's now been used in hundreds of thousands of patients around the world.
-
Decades-old law limits access to Wegovy for Medicaid beneficiaries
New medications like Wegovy are changing the way people lose weight and manage obesity, but many Medicaid beneficiaries can't get them.
-
National
States consider whether to add coverage for some obesity medicines
Medicaid is required to cover almost all drugs, but Congress specifically excluded those for weight loss. Even so, 16 states now cover Wegovy. Others are considering it, but it could strain budgets.
-
Oncologists' meetings with drug reps don't help cancer patients live longer
Drug company reps commonly visit doctors to talk about new medications. A team of economists wanted to know if that helps patients live longer. They found that for cancer patients, the answer is no.
-
National
Pharma reps have visited doctors for decades. What impact does it have on patients?
A economic research study shows that oncologists' prescribing habits change after they've been visited by pharmaceutical sales reps — and it also shows the changes do not extend patients' lives.
-
Persistent shortage of growth hormone frustrates parents and clinicians
As a shortage of growth hormone used to treat rare diseases in children drags on, families and doctors are struggling with insurers' requirements to get prescriptions filled.
-
Drugmakers' low U.S. taxes belie their high sales
Most of the largest pharmaceutical companies report losing money in the United States, despite the majority of their sales coming from Americans. The result is lower U.S. taxes for the companies.
-
National
U.S. drug makers see big profits — but many pay taxes far below the corporate rate
Drugmakers make big profits in the U.S. But many pay taxes far below the 21% corporate tax rate. Pfizer's effective tax rate is so low it's getting a big refund despite booking $59 billion in revenue.
-
First over-the-counter birth control pill heads to stores
Women will be able to buy the pill without a prescription later this month at pharmacies and grocery stores.
-
Bayer makes a deal on popular contraceptive with Mark Cuban's online pharmacy
Bayer is adding two of its name-brand drugs to the roster of Cost Plus Drugs: the birth control pill Yaz and the menopause treatment Climara.